Effects of Sertralin and Duloxetin in treatment of IBS
Phase 3
Recruiting
- Conditions
- Irritable bowel syndrome.Irritable bowel syndrome
- Registration Number
- IRCT20210420051023N1
- Lead Sponsor
- Birjand University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 192
Inclusion Criteria
No receiving psychological therapies before entering the study
Not having other structural or functional gastrointestinal disorders at the same time
Not suffering from other organic diseases
Not having psychotic disorder and personality disorder
No risk symptoms such as gastrointestinal bleeding, blood in the stool, fever, weight loss, anemia, nocturnal diarrhea, severe heartburn, etc.,
Exclusion Criteria
Consuming alcohol and substances abuse
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Depression score in Beck questionnaire. Timepoint: First study and 30 days after the start of sertraline and duloxetine. Method of measurement: Beck Depression Inventory.
- Secondary Outcome Measures
Name Time Method